<b>Methods:</b> This retrospective study included patients with advanced EGFR/ALK-negative non-squamous NSCLC treated with first-line I + C + B or I + C. Propensity score matching (PSM) was employed to balance baseline characteristics between groups. This evidence concerns the gene EGFR and non-small cell lung carcinoma.